NEMLUVIO's Patent Extension: FDA Times It Just Right
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for NEMLUVIO, a human biological product, so its patent can be extended. This means the company behind NEMLUVIO gets extra time to protect their invention and keep making money. Anyone interested in drug patents or new medicines should watch this space for timing and legal updates.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension OK for NEMLUVIO
The FDA has determined the regulatory review period for NEMLUVIO so the patent on that human biological product can be extended. This gives the company behind NEMLUVIO extra time to protect its invention and continue earning revenue from the product.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in